Effect of fractalkine-Fc delivery in experimental lung metastasis using DNA/704 nanospheres

Cancer Gene Therapy

Volumn 18, Issue 11, 2011, Pages 761-772

  Richard Fiardo, P ^a,b   Cambien, B ^a,b   Pradelli, E ^a,b   Beilvert, F ^c,d   Pitard, B ^c,d,e   Schmid Antomarchi, H ^a,b   Schmid Alliana, A ^a,b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c L INSTITUT DU THORAX   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e In Cell Art   (France)

Author keywords

chemokines; experimental lung metastases; gene delivery systems; tumor immunotherapy

Indexed keywords

AMPHOPHILE; BLOCK COPOLYMER 704; CHLORAMPHENICOL ACETYLTRANSFERASE; COPOLYMER; FC RECEPTOR; FRACTALKINE; NANOSPHERE; PLASMID DNA; POLOXAMER; POLYETHYLENEIMINE; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DRUG FORMULATION; EXPRESSION VECTOR; FEMALE; GENE TARGETING; GENE VECTOR; LUNG METASTASIS; LUNG NODULE; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ANIMALS; CELL LINE, TUMOR; CHEMOKINE CX3CL1; DRUG DELIVERY SYSTEMS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; LUNG NEOPLASMS; MICE; NANOSPHERES; NEOPLASM METASTASIS; PLASMIDS; TRANSFECTION;

EID: 80054737746     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.42     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2002; 2: 175-184. (Pubitemid 37328764)
3. Rosenblatt JD, Shin SU, Nechustan H, Yi KH, Tolba K. Potential role of chemokines in immune therapy of cancer. Isr Med Assoc J 2002; 4: 1054-1059.
4. Flanagan K, Kaufman HL. Chemokines in tumor immunotherapy. Front Biosci 2006; 11: 1024-1030. (Pubitemid 43253458)
5. Gao JQ, Okada N, Mayumi T, Nakagawa S. Immune cell recruitment and cell-based system for cancer therapy. Pharm Res 2008; 25: 752-768.
6. Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M. The high expression of fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 2005; 26: 41-47.
7. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010; 138: 1429-1440.
8. Lavergne E, Combadiere B, Bonduelle O, Iga M, Gao JL, Maho M et al. Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res 2003; 63: 7468-7474. (Pubitemid 37413490)
9. Guo J, Zhang M, Wang B, Yuan Z, Guo Z, Chen T et al. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int J Cancer 2003; 103: 212-220. (Pubitemid 35461513)
10. Zeng Y, Jiang J, Huebener N, Wenkel J, Gaedicke G, Xiang R et al. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. Cancer Lett 2005; 228: 187-193. (Pubitemid 41188441)
11. Xin H, Kikuchi T, Andarini S, Ohkouchi S, Suzuki T, Nukiwa T et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005; 35: 1371-1380. (Pubitemid 40691418)
12. Nukiwa M, Andarini S, Zaini J, Xin H, Kanehira M, Suzuki T et al. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur J Immunol 2006; 36: 1019-1027.
13. Vitale S, Cambien B, Karimdjee BF, Barthel R, Staccini P, Luci C et al. Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut 2007; 56: 365-372. (Pubitemid 46579766)
14. Brueckmann M, Borggrefe M. Therapeutic potential of fractalkine: a novel approach to metastatic colon cancer. Gut 2007; 56: 314-316. (Pubitemid 46579755)
15. Xin H, Sun R, Kanehira M, Takahata T, Itoh J, Mizuguchi H et al. Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to multiple lung tumors. Mol Med 2009; 15: 321-327.
16. Momin EN, Mohyeldin A, Zaidi HA, Vela G, Quinones-Hinojosa A. Mesenchymal stem cells: new approaches for the treatment of neurological diseases. Curr Stem Cell Res Ther 2010; 5: 326-344.
17. Bar J, Herbst RS, Onn A. Targeted drug delivery strategies to treat lung metastasis. Expert Opin Drug Deliv 2009; 6: 1003-1016.
18. Densmore CL, Orson FM, Xu B, Kinsey BM, Waldrep JC, Hua P et al. Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol Ther 2000; 1: 180-188.
19. Goula D, Becker N, Lemkine GF, Normandie P, Rodrigues J, Mantero S et al. Rapid crossing of the pulmonary endothelial barrier by polyethylenimine/DNA complexes. Gene Ther 2000; 7: 499-504. (Pubitemid 30156564)
20. Desigaux L, Gourden C, Bello-Roufä M, Richard P, Oudrhiri N, Lehn P et al. Nonionic amphiphilic block copolymers promote gene transfer to the lung. Hum Gene Ther 2005; 16: 821-829. (Pubitemid 40982331)
21. Pitard B, Bello-Roufä M, Lambert O, Richard P, Desigaux L, Fernandes S et al. Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. Nucleic Acids Res 2004; 32: e159.
22. Ferrari S, Moro E, Pettenazzo A, Behr JP, Zacchello F, Scarpa M. ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo. Gene Ther 1997; 4: 1100-1106. (Pubitemid 27469941)
23. McIlroy D, Barteau B, Cany J, Richard P, Gourden C, Conchon S et al. DNA/amphiphilic block copolymer nanospheres promote low-dose DNA vaccination. Mol Ther 2009; 17: 1473-1481.
24. Pollard H, Remy JS, Loussouarn G, Demolombe S, Behr JP, Escande D. Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J Biol Chem 1998; 273: 7507-7511. (Pubitemid 28152775)
25. Piron J, Quang KL, Briec F, Amirault JC, Leoni AL, Desigaux L et al. Biological pacemaker engineered by nonviral gene transfer in a mouse model of complete atrioventricular block. Mol Ther 2008; 16: 1937-1943.
26. Ziady AG, Gedeon CR, Miller T, Quan W, Payne JM, Hyatt SL et al. Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol Ther 2003; 8: 936-947. (Pubitemid 38072306)
27. Loebinger MR, Janes SM. Stem cells as vectors for antitumour therapy. Thorax 2010; 65: 362-369.
28. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lungdirected gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
29. Van Ginkel FW, Liu C, Simecka JW, Dong JY, Greenway T, Frizzell RA et al. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Hum Gene Ther 1995; 6: 895-903.
30. Guo J, Chen T, Wang B, Zhang M, An H, Guo Z et al. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 2003; 89: 1-7. (Pubitemid 37289511)
31. Tang DW, Li LF, Yu YM, Liu XY, Su XD, Zhao X et al. Preparation, crystallization and preliminary X-ray analysis of threonine synthase from Streptococcus mutans. Protein Pept Lett 2007; 14: 836-838. (Pubitemid 47416410)
32. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170: 827-845. (Pubitemid 19226667)
33. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992; 143: 127-142.
34. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177: 1199-1204. (Pubitemid 23097410)
35. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547-549. (Pubitemid 23161621)